HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Rac-(1r,4r)-4-methoxycyclohexane-1-carboxylic acid
cis-4-Methoxycyclohexanecarboxylic acid · cis-4-methoxycyclohexane-1-carboxylic acid · (1S,4S)-4-METHOXYCYCLOHEXANECARBOXYLIC ACID · Cyclohexanecarboxylic acid, 4-methoxy-, cis- · (1s,4s)-4-Methoxycyclohexane-1-carboxylic acid · rel-(1S,4S)-4-Methoxycyclohexanecarboxylic acid · rel-(1s,4s)-4-methoxycyclohexane-1-carboxylic acid · cis-4-methoxycyclohexanecarboxylic acid - [M25142]

Identifikatoren & physikalische Daten
| CAS No. | 73873-59-3 |
|---|---|
| Summenformel | C8H14O3 |
| Durchschnittliche Molmasse | 158,19 g/mol |
| Monoisotopische Masse | 158,09429431 g/mol |
| SMILES | COC1CCC(C(=O)O)CC1 |
| InChIKey | WKILSRYNRQGRMA-UHFFFAOYSA-N |
| PubChem CID | 736153 |
| EC No. | 892-635-2 |
| DTXSID | DTXSID801347396 |
Chemische & physikalische Eigenschaften
| XLogP | 0,9 |
|---|---|
| Polarare Oberfläche (TPSA) | 46,5 |
| H-Brücken-Donoren | 1 |
| H-Brücken-Akzeptoren | 3 |
| Frei drehbare Bindungen | 2 |
| Schwere Atome | 11 |
| Formalladung | 0 |
| Komplexität | 136 |
| Schmelzpunkt | 54.8-55.8 °C |
| Siedepunkt | 266.6±33.0 °C(Predicted) |
| Dichte | 1.09±0.1 g/cm3(Predicted) |
| Lagerbedingungen | Store at 0-8 °C |
| pKa (Säurekonstante) | 4.81±0.25(Predicted) |
Sicherheit & Vorschriften
| GHS-Einstufung | WarningH315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. |
|---|---|
| Hazard Classes and Categories | Skin Irrit. 2 (100%) |
| Alarmwort | Achtung |
| Gefahrenhinweise | Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H301 |
Anwendungen & Verwendung
Verwenden
cis-4-Methoxycyclohexane-1-carboxylic Acid is used in the preparation of tricyclic guanidine derivs. useful as inhibitors of PDE1 in the treatment of neurological or psychiatric disorders.